Compare Nvidia Corp (NVDA) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs Recursion Pharmaceuticals Inc — how do they compare? Nvidia Corp trades at $233.25 (market cap $5.73T), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.31B). The key difference: Nvidia Corp is far larger — about 2480.5× Recursion Pharmaceuticals Inc's market cap, and Nvidia Corp pays a 0.42% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nvidia Corp for 115 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| NVDA | RXRX | |
|---|---|---|
Market Cap | $5.73T | $2.31B |
Volume | 81,027,431 | 40,478,768 |
Sector | Technology | Health |
52-Week High | $239.27 | $6.79 |
52-Week Low | $165.17 | $2.84 |
Typical Hold Time | 115 Days | 22 Days |
Enterprise Value | $5.71T | $1.83B |
Dividend Yield | 0.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $230.48, down 3.67% on the day, amid a broader tech sell-off. The stock maintains a bullish technical signal with strong moving averages, though oscillators are neutral and RSI levels suggest potential overbought conditions. Fundamentally, the company reported robust revenue of $130.50B in 2025 with a net income margin of 63.66%, and it has consistently beaten earnings expectations in recent quarters. Recent news highlights AI-driven growth prospects but also notes concerns about market saturation and geopolitical impacts on U.S. equities.
The outlook for NVDA remains positive due to its dominant position in AI chips and accelerating revenue growth, with Wall Street consensus pointing to significant upside from the current price. Key risks include heightened competition, peak AI spending cycles, and macroeconomic volatility. The stock presents a compelling opportunity for growth-oriented investors, but requires monitoring of execution risks and market sentiment shifts.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
